196 related articles for article (PubMed ID: 19876039)
1. Asenapine.
Meltzer HY; Dritselis A; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2009 Nov; 8(11):843-4. PubMed ID: 19876039
[TBL] [Abstract][Full Text] [Related]
2. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
[TBL] [Abstract][Full Text] [Related]
3. Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania.
Tarazi FI; Shahid M
Drugs Today (Barc); 2009 Dec; 45(12):865-76. PubMed ID: 20135021
[TBL] [Abstract][Full Text] [Related]
4. ACS chemical neuroscience molecule spotlight on Saphris.
Hopkins CR
ACS Chem Neurosci; 2010 Apr; 1(4):263-4. PubMed ID: 22778826
[TBL] [Abstract][Full Text] [Related]
5. Asenapine: a clinical review of a second-generation antipsychotic.
Stoner SC; Pace HA
Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521
[TBL] [Abstract][Full Text] [Related]
6. Iloperidone, asenapine and lurasidone: a primer on their current status.
Tarazi FI; Stahl SM
Expert Opin Pharmacother; 2012 Sep; 13(13):1911-22. PubMed ID: 22849428
[TBL] [Abstract][Full Text] [Related]
7. Asenapine approved for treatment of schizophrenia, bipolar disorder.
Traynor K
Am J Health Syst Pharm; 2009 Sep; 66(18):1596. PubMed ID: 19729558
[No Abstract] [Full Text] [Related]
8. Asenapine (Saphris) sublingual tablets for schizophrenia and bipolar disorder.
Med Lett Drugs Ther; 2010 Feb; 52(1331):9-10. PubMed ID: 20216523
[No Abstract] [Full Text] [Related]
9. Asenapine: Pharmacological Aspects and Role in Psychiatric Disorders.
Reyad AA; Mishriky R
Psychiatr Danub; 2019 Jun; 31(2):157-161. PubMed ID: 31291219
[TBL] [Abstract][Full Text] [Related]
10. Asenapine: a review of acute and extension phase data in bipolar disorder.
McIntyre RS
CNS Neurosci Ther; 2011 Dec; 17(6):645-8. PubMed ID: 20950326
[TBL] [Abstract][Full Text] [Related]
11. New drug information. Saphris.
Physician Assistants Prescribing Reference
JAAPA; 2010 Mar; 23(3):16. PubMed ID: 20232719
[No Abstract] [Full Text] [Related]
12. Asenapine.
Weber J; McCormack PL
CNS Drugs; 2009 Sep; 23(9):781-92. PubMed ID: 19689168
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics: the two new arrivals.
Roman MW
Issues Ment Health Nurs; 2011; 32(1):85-6. PubMed ID: 21208056
[No Abstract] [Full Text] [Related]
14. A Review of Asenapine in the Treatment of Bipolar Disorder.
Vieta E; Montes JM
Clin Drug Investig; 2018 Feb; 38(2):87-99. PubMed ID: 29067671
[TBL] [Abstract][Full Text] [Related]
15. Asenapine review, part II: clinical efficacy, safety and tolerability.
Citrome L
Expert Opin Drug Saf; 2014 Jun; 13(6):803-30. PubMed ID: 24793161
[TBL] [Abstract][Full Text] [Related]
16. Asenapine: a new antipsychotic option.
Henry JM; Fuller MA
J Pharm Pract; 2011 Oct; 24(5):447-51. PubMed ID: 22156709
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical pinpoint pupils with asenapine.
Gill JS; Jambunathan S; Wong S; Wong A
Asia Pac Psychiatry; 2015 Jun; 7(2):230. PubMed ID: 25923587
[No Abstract] [Full Text] [Related]
18. Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: meta-analyses of randomized-controlled trials.
Vita A; De Peri L; Siracusano A; Sacchetti E;
Int Clin Psychopharmacol; 2013 Sep; 28(5):219-27. PubMed ID: 23719049
[TBL] [Abstract][Full Text] [Related]
19. Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial.
Findling RL; Landbloom RL; Mackle M; Wu X; Snow-Adami L; Chang K; Durgam S
Paediatr Drugs; 2016 Oct; 18(5):367-78. PubMed ID: 27461426
[TBL] [Abstract][Full Text] [Related]
20. New drugs: asenapine, iloperidone, and bepotastine besilate.
Hussar DA; Abbas CA
J Am Pharm Assoc (2003); 2010; 50(1):107-10. PubMed ID: 20097650
[No Abstract] [Full Text] [Related]
[Next] [New Search]
